Allied Biotech Corporation
Allied Biotech Corporation, a leading name in the biotechnology sector, is headquartered in Taiwan (TW) and operates extensively across Asia, Europe, and North America. Founded in 1995, the company has established itself as a pioneer in the development of innovative biopharmaceuticals and advanced drug delivery systems. Specialising in the production of high-quality excipients and active pharmaceutical ingredients (APIs), Allied Biotech is renowned for its commitment to quality and regulatory compliance. Their unique offerings, including proprietary formulations and customised solutions, cater to a diverse range of therapeutic areas. With a strong market position, Allied Biotech has achieved significant milestones, including numerous partnerships with global pharmaceutical companies. Their dedication to research and development continues to drive advancements in the industry, solidifying their reputation as a trusted partner in biopharmaceutical innovation.
DitchCarbon Score
How does Allied Biotech Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Allied Biotech Corporation's score of 39 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Allied Biotech Corporation's reported carbon emissions
In 2024, Allied Biotech Corporation reported total carbon emissions of approximately 8,751,177 kg CO2e, comprising 315,123.1 kg CO2e from Scope 1, 1,110,520 kg CO2e from Scope 2, and 2,709,695.6 kg CO2e from Scope 3. This reflects a decrease from 2023, where total emissions were about 9,112,792 kg CO2e, with Scope 1 emissions at 237,628.4 kg CO2e, Scope 2 at 583,750 kg CO2e, and Scope 3 at 2,833,556.5 kg CO2e. Allied Biotech has set ambitious reduction targets, aiming for a 10% reduction in total carbon emissions for both Scope 1 and Scope 2 by 2023, which they achieved. Looking ahead, the company has committed to a medium-term goal of reducing Scope 1 and 2 emissions by 50% and Scope 3 emissions by 30% by 2030, based on scientific-based targets. Furthermore, they have a long-term commitment to achieve net-zero emissions by 2050, aligning with the Science-Based Targets initiative (SBTi) to limit global temperature rise to no more than 1.5°C. The emissions data is not cascaded from any parent organization, indicating that Allied Biotech Corporation independently reports its carbon footprint and climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 237,628.4 | 000,000.0 |
| Scope 2 | 583,750 | 0,000,000 |
| Scope 3 | 2,833,556.5 | 0,000,000.0 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Allied Biotech Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
